Researchers explore the cellular and molecular adaptations associated with human secondary lymphoid tissue in adults during viral infection.
As Sarepta execs talk up Duchenne confirmatory trial results, investors and analysts remain divided on how flexible FDA will be
Anyone listening to Sarepta’s call Monday after the biotech released trial data for its Duchenne muscular dystrophy gene therapy would have thought the company hit
November 1, 2023